Myriad Genetics, Inc. MYGN
5.85 USD +0.13 (+2.27%)
Nov 12, 2026, 1:18 PM EST
5.47 Day range 5.86
2.74 52-week range 8.09
- YTD
- -4.88%
- 1 year
- -10.55%
News
benzinga.com Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6 Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and raises the price target from $3 to $6.
seekingalpha.com Myriad Genetics, Inc. (MYGN) Presents at 2026 UBS Global Healthcare Conference Transcript Myriad Genetics, Inc. ( MYGN ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Samraat Raha - President, CEO & Director Ben Wheeler - CFO & Principal…
benzinga.com TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75 TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4.5 to $6.75.
benzinga.com Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8 Leerink Partners analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and raises the price target from $5 to $8.
seekingalpha.com Myriad Genetics, Inc. (MYGN) Q3 2026 Earnings Call Transcript Myriad Genetics, Inc. ( MYGN ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO &…
benzinga.com Myriad Genetics Q3 2026 Earnings Call Transcript Myriad Genetics (NASDAQ:MYGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Myriad Genetics Raises FY2026 Sales Guidance from $770.000M-$790.000M to $780.000M-$790.000M vs $777.921M Est Myriad Genetics (NASDAQ:MYGN) raises FY2026 sales outlook from $770.000 million-$790.000 million to $780.000 million-$790.000 million vs $777.921 million estimate.
benzinga.com Myriad Genetics Q3 Adj. EPS $(0.11) Beats $(0.20) Estimate, Sales $202.700M Beat $191.329M Estimate Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. The company reported quarterly sales of $202.700…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
benzinga.com Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
benzinga.com Nasdaq Rises Over 100 Points; 3M Earnings Top Views U.S. stocks rose Tuesday, led by the Dow, as 3M beat estimates. Braze and Myriad surged, while GM fell; oil and silver gained.
benzinga.com Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed; Dow rose 400 points. Hasbro surged on strong earnings and outlook, while Braze, Myriad Genetics and others gained.
benzinga.com Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center…
benzinga.com TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5 TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4 to $4.5.- benzinga.com SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support…
- benzinga.com Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8 Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…- benzinga.com Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
benzinga.com Why RH Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket RH shares jumped 8.2% premarket after EPS beat estimates despite a revenue miss; Oracle and others gained, while OPTT and ZUMZ fell.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after-market session. The company's market cap stands at $11.5 million. Picard Medical (AMEX:PMI) stock moved…- benzinga.com UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6 UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.
benzinga.com Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Cango Inc (NYSE:CANG) fell sharply in pre-market trading as the company posted…
benzinga.com Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3 Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5 to $3.
benzinga.com Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3 Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
- benzinga.com TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $4 TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $6 to $4.
benzinga.com Crude Oil Gains 1%; Apple Shares Tumble After Q3 Results Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, materials stocks down 2.7%. Apple beats estimates, shares down 9%.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
benzinga.com Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.
benzinga.com Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pre-market trading while other stocks also saw gains/losses.
benzinga.com Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
- benzinga.com Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to $770.000 million-$790.000 million vs $863.568 million estimate.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market session. Onconetix (NASDAQ:ONCO) shares moved upwards by 27.46% to $0.96. The company's market cap stands at…
benzinga.com Myriad Genetics Announces Expanded Availability Of Precise MRD To Patients Undergoing Treatment And Surveillance For Breast, Colorectal And Renal Cancers Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients…
benzinga.com TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $6 TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $7 to $6.- benzinga.com Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $5.5 Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $6 to $5.5.
- benzinga.com Myriad Genetics Affirms FY2026 Sales Guidance of $860.000M-$880.000M vs $864.099M Est Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $860.000 million-$880.000 million to $860.000 million-$880.000 million vs $864.099 million estimate.
- benzinga.com Myriad Genetics Q1 Adj. EPS $(0.09) Misses $(0.07) Estimate, Sales $200.400M Miss $202.484M Estimate Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 200 percent decrease over losses of…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Myriad Genetics Receives Japan Approval For MyChoice Test For Prostate Cancer Patients Myriad Genetics Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the use…
- benzinga.com Myriad Genetics Gets FDA Approval Of MyChoice CDx Test As Companion Diagnostic For Zejula, PARP Inhibitor From GSK, For Patients With Advanced Ovarian Cancer Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx…
- benzinga.com UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $6 UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $8 to $6.
- benzinga.com Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $6 Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $6.5 to $6.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
benzinga.com Myriad Genetics Earnings Report: Q4 Overview - benzinga.com Myriad Genetics Sees FY2026 Sales $860.000M-$880.000M vs $867.455M Est Myriad Genetics (NASDAQ:MYGN) sees FY2026 sales of $860.000 million-$880.000 million vs $867.455 million analyst estimate.
- benzinga.com Myriad Genetics Q4 Adj. EPS $0.04 Beats $(0.01) Estimate, Sales $209.800M Beat $207.366M Estimate Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.01) by 366.67 percent. This is a 33.33 percent increase over earnings of…
- benzinga.com Earnings Scheduled For February 23, 2026